74 results on '"Jansen, T"'
Search Results
2. 2016 updated EULAR evidence-based recommendations for the management of gout
3. POS1124 IDENTIFYING POTENTIAL CLASSIFICATION CRITERIA FOR CALCIUM PYROPHOSPHATE DEPOSITION DISEASE (CPPD): RESULTS FROM THE INITIAL PHASES
4. AB0915-PARE DEVELOPMENT AND USABILITY OF A WEB-BASED PATIENT-TAILORED TOOL TO SUPPORT ADHERENCE TO URATE-LOWERING THERAPY IN GOUT PATIENTS
5. POS1053 COMPARISON OF BASELINE CHARACTERISTICS BETWEEN PATIENTS CONTINUING OR DISCONTINUING APREMILAST AT TWELVE MONTHS IN THE REWARD STUDY (THE NETHERLANDS)
6. AB0784 COMPARABLE IMPACT AND BURDEN OF DISEASE OF PSORIATIC ARTHRITIS PATIENTS WITH LIMITED JOINT INVOLVEMENT VS. THOSE WITH MORE EXTENSIVE JOINT INVOLVEMENT: INTERIM RESULTS FROM THE REWARD STUDY, A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN PATIENTS TREATED WITH APREMILAST
7. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis
8. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies
9. The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data
10. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
11. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
12. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?
13. A DIAGNOSTIC PERFORMANCE STUDY ON RAMAN SPECTROSCOPY INTEGRATED WITH POLARIZED LIGHT MICROSCOPY FOR THE IDENTIFICATION OF MONOSODIUM URATE IN GOUT.
14. 2016 updated EULAR evidence-based recommendations for the management of gout
15. OP0181 Prediction of Flare after Stopping TNF-Inhibitor by Baseline Ultrasonography and Patient Characteristics in Rheumatoid Arthritis Patients with Low Disease Activity: 12-Month Results
16. MICROPLASTIC POLLUTION IN SYNOVIAL FLUID SAMPLES FROM SWOLLEN JOINTS ANALYZED WITH RAMAN SPECTROSCOPY.
17. RATIONALE AND DESIGN FOR PODAGRA II: A MULTICENTER RANDOMIZED PHASE 2/3 STUDY ASSESSING THE EFFICACY AND SAFETY OF DAPANSUTRILE, AN ORALLY ADMINISTERED SPECIFIC INHIBITOR OF THE NLRP3 INFLAMMASOME IN SUBJECTS WITH AN ACUTE GOUT FLARE.
18. LESSONS TO BE LEARNED FROM REAL LIFE DATA FROM 98 GOUT PATIENTS USING A URICOSURIC: BENZBROMARONE.
19. CALCIUM CONTAINING CRYSTALS ARE HIGHLY PREVALENT IN JOINT FLUID OF ADVANCED OSTEOARTHRITIS OF THE KNEE.
20. FRI0345 Tapering MTX in Patients with RA Using TNFI Treatment is Possible: Table 1.
21. SAT0321 What Should Be the Cut Point for Classification Criteria for Studies in Gout? A Conjoint Analysis
22. OP0181 Ultrasonography as Predictor for Flare in Rheumatoid Arthritis Patients with Low Disease Activity: Nine Month Results from Poet-Us-Study
23. AB1095 Adverse Events from Diagnostic Arthrocentesis for Suspicion of Gout: A Systematic Analysis in a Large Multi-Centre Cohort
24. AB0826 Imaging Modalities for the Classification of Gout: Systematic Literature Review and Meta-Analysis
25. SAT0532 Updated Eular Evidence-Based Recommendations for the Diagnosis of Gout
26. SAT0531 Updated Eular Evidence-Based Recommendations for the Management of Gout
27. THU0493 Association of the Toll-Like Receptor 4 (TLR4) Gene with Gout
28. THU0168 How Low Should You Go? Towards Personalized Treatment Targets for Disease Activity in RA
29. AB0629 A critical appraisal of the competence of crystal identification by rheumatologists.
30. THU0577 Protocol-Bvased Pharmacotherapy in Gout Delivered by Specialised Health Care Professional Under Supervision of a Rheumathologist is Similar but not Significantly Superior to Care as Usual
31. OP0069 Significantly Better Results for TNFI Combination Therapy with MTX Than TNFI Mono- and Combination Without MTX Therapy in Patients with RA: Results from the Dream Registry
32. THU0152 The Poet-Us Study: Can Ultrasonography Predict Flare in Patients with RA and Persistent Low Disease Activity in Whom the Tnfinhibitor (TNFI) is Stopped? Preliminary Results of an Ongoing Study
33. Switching from aurothioglucose to aurothiumalate: An observational study
34. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management
35. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis
36. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
37. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis
38. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
39. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies
40. Survey on management of gout among Dutch rheumatologists
41. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
42. The effectiveness and medication costs of three anti-tumour necrosis factor agents in the treatment of rheumatoid arthritis from prospective clinical practice data
43. A clinical and serological comparison of group A versus non-group A streptococcal reactive arthritis and throat culture negative cases of post-streptococcal reactive arthritis
44. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout.
45. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
46. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout
47. Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker.
48. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.
49. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.
50. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.